cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
,
INDONESIA
The Indonesian Biomedical Journal
Published by The Prodia Education and Research Institute
ISSN : -     EISSN : -     DOI : -
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Public Health
Arjuna Subject : -
Articles 13 Documents
 1   2 
Search results for , issue "Vol 13, No 2 (2021)" : 13 Documents clear
Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study Astuti Giantini; Ina Susianti Timan; Erlin Listiyaningsih; Rahajuningsih Dharma; Rianto Setiabudy; Idrus Alwi; Lia Gardenia Partakusuma; Nuri Dyah Indrasari; Alida Roswita Harahap; Siskawati Suparmin; Windy Sahar; Renan Sukmawan
The Indonesian Biomedical Journal Vol 13, No 2 (2021)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v13i2.1477

Abstract

BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in patients undergoing percutaneous coronary intervention and determine factors affecting clopidogrel resistance.METHODS: The subjects were 119 patients who underwent percutaneous coronary intervention (PCI) and had given loading dose of 600 mg clopidogrel. Blood samples were taken at 6 hour after clopidogrel loading dose. Platelet aggregation was measured by LTA and VerifyNow.RESULTS: LTA and VerifyNow assay showed fair agreement with Kappa=0.270, p=0.001. The proportion of resistance to clopidogrel using VerifyNow was 21.8% and LTA was 47.1%. Patients with diabetes melitus were more likely to develop clopidogrel resistance than patients without diabetes (OR of 7.67; 95% CI: 1.87-31.50; p=0.005).CONCLUSION: The ability of LTA and VerifyNow in detecting clopidogrel resistance were not comparable. Multivariate analysis results for VerifyNow shows diabetes mellitus as the greatest predictors of clopidogrel resistance.KEYWORDS: agreement, clopidogrel resistance, LTA, predictor, VerifyNow 
Soluble Transferrin Receptor and Soluble Transferrin Receptor/Log Ferritin Ratio are Correlated with Iron Status in Regular Hemodialysis Patients Yenny Kandarini; Gede Wira Mahadita; Sianny Herawati; Anak Agung Wiradewi Lestari; Ketut Suega; I Gde Raka Widiana
The Indonesian Biomedical Journal Vol 13, No 2 (2021)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v13i2.1412

Abstract

BACKGROUND: Monitoring of iron status in chronic kidney disease patients is important, however inflammation may hinder its monitoring. Soluble transferrin receptor (sTfR) is an alternative parameter to overcome this issue, whereas ferritin play a part in the inflammation process. Hence, the correlation between the sTfR ratio and the sTfR/log ferritin ratio with conventional iron status parameters in regular hemodialysis patients is necessary to be evaluated.METHODS: A cross-sectional was conducted in the current study. As many as 5 mL of blood (2 mL for sTfR and 3 mL for serum iron and ferritin levels) was collected. sTfR level was the blood-soluble transferrin receptor level measured by the enzyme-linked immunosorbent assay (ELISA). The amount of ferritin and serum iron was determined using the immunochemiluminescent process. To evaluate the correlation, the Pearson correlation test was used.RESULTS: A total of 80 subjects was included in this study. The mean of hemoglobin was 10.25±1.66 g/dL, serum iron was 58.19±26.56 g/dL, and the median ferritin was 520.4 (49.9-3606) ng/mL. The sTfR was significantly associated only with serum iron levels with a correlation coefficient of r=-0.242; p=0.031. The sTfR/log ferritin was significantly associated with serum iron l evels (InSI)(r=-0.255, p=0.022); and transferrin saturation (r=-0.295; p=0.008).CONCLUSION: sTfR/log ferritin has a negative and significant correlation with serum iron levels and transferrin saturation, while sTfR negatively correlated with serum iron levels. sTfR and sTfR/log ferritin may be considered as an alternative iron marker in inflammation setting such as CKD.KEYWORDS: sTfR/log ferritin, iron status, serum iron, ferritin, chronic kidney disease, hemodialysis
Metabolic Reprogramming and Molecular Rewiring in Cancer: Therapeutic Opportunities Anna Meiliana; Nurrani Mustika Dewi; Andi Wijaya
The Indonesian Biomedical Journal Vol 13, No 2 (2021)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v13i2.1598

Abstract

BACKGROUND: A lot of contemporary cancer research has concentrated on genetic influence. However, cancer also involves biochemical changes, such as metabolic adaptation to support the aberrant cell proliferation.CONTENT: The fast cell proliferation in cancer cells enforce a metabolic re-arrangement to promote their long-term survival. The increased glucose uptake and fermentation of glucose to lactate are common features of this altered metabolism known as “the Warburg effect”. These metabolic pathways regulation enable cancer cells to produce adenosine triphosphate (ATP) in an efficient way. Epigenetic and metabolic changes also both affect molecular rewiring in cancer cells and promote cancer development and progression.SUMMARY: Metabolic rewiring and epigenetic remodeling establishing a direct link between metabolism and nuclear transcription to promote the survival of tumor cells. A further understanding of how metabolic remodeling can result in epigenetic changes in tumors, affecting cancer cell differentiation, proliferation, and/or apoptosis, will lead to a new strategy for cancer therapy.KEYWORDS: cancer metabolism, epigenetics, metabolic reprogramming, molecular rewiring

Page 2 of 2 | Total Record : 13

 1   2 

Filter by Year

2021 2021


Reset
Filter By Issues
All Issue Vol 18, No 1 (2026) Vol 17, No 6 (2025) Vol 17, No 5 (2025) Vol 17, No 4 (2025) Vol 17, No 3 (2025) Vol 17, No 2 (2025) Vol 17, No 1 (2025) Vol 16, No 6 (2024) Vol 16, No 5 (2024) Vol 16, No 4 (2024) Vol 16, No 3 (2024) Vol 16, No 2 (2024) Vol 16, No 1 (2024) Vol 15, No 6 (2023) Vol 15, No 5 (2023) Vol 15, No 4 (2023) Vol 15, No 3 (2023) Vol 15, No 2 (2023) Vol 15, No 1 (2023) Vol 14, No 4 (2022) Vol 14, No 3 (2022) Vol 14, No 2 (2022) Vol 14, No 1 (2022) Vol 13, No 4 (2021) Vol 13, No 3 (2021) Vol 13, No 2 (2021) Vol 13, No 1 (2021) Vol 12, No 4 (2020) Vol 12, No 3 (2020) Vol 12, No 2 (2020) Vol 12, No 1 (2020) Vol 11, No 3 (2019) Vol 11, No 2 (2019) Vol 11, No 1 (2019) Vol 10, No 3 (2018) Vol 10, No 2 (2018) Vol 10, No 1 (2018) Vol 9, No 3 (2017) Vol 9, No 2 (2017) Vol 9, No 1 (2017) Vol 8, No 3 (2016) Vol 8, No 2 (2016) Vol 8, No 1 (2016) Vol 7, No 3 (2015) Vol 7, No 2 (2015) Vol 7, No 1 (2015) Vol 7, No 1 (2015) Vol 6, No 3 (2014) Vol 6, No 2 (2014) Vol 6, No 1 (2014) Vol 5, No 3 (2013) Vol 5, No 2 (2013) Vol 5, No 1 (2013) Vol 4, No 3 (2012) Vol 4, No 2 (2012) Vol 4, No 1 (2012) Vol 3, No 3 (2011) Vol 3, No 2 (2011) Vol 3, No 1 (2011) Vol 2, No 3 (2010) Vol 2, No 2 (2010) Vol 2, No 1 (2010) Vol 1, No 3 (2009) Vol 1, No 2 (2009) Vol 1, No 1 (2009) More Issue